AC Immune (NASDAQ:ACIU) Lowered to Sell Rating by Wall Street Zen

AC Immune (NASDAQ:ACIU) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other analysts also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, January 21st. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of AC Immune in a research note on Tuesday, November 4th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

AC Immune Trading Down 6.2%

Shares of ACIU opened at $3.19 on Friday. The stock has a 50 day moving average of $3.21 and a 200 day moving average of $2.87. The company has a market capitalization of $320.31 million, a price-to-earnings ratio of -3.80 and a beta of 1.62. AC Immune has a 12 month low of $1.43 and a 12 month high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $0.81 million. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%. As a group, equities research analysts predict that AC Immune will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On AC Immune

Several hedge funds have recently made changes to their positions in ACIU. Assenagon Asset Management S.A. bought a new stake in shares of AC Immune during the 3rd quarter valued at $549,000. Acadian Asset Management LLC increased its position in shares of AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares during the period. Sei Investments Co. purchased a new stake in shares of AC Immune in the second quarter worth about $51,000. Susquehanna International Group LLP purchased a new stake in shares of AC Immune in the third quarter worth about $63,000. Finally, Private Advisor Group LLC bought a new position in shares of AC Immune in the third quarter valued at approximately $48,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.